BioArctic AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRCTF research report →
About the company
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases.
- CEO
- Gunilla Christina Osswald
- IPO
- 2022
- Employees
- 131
- HQ
- Stockholm, BC, SE
Price Chart
- Market Cap
- $3.11B
- P/E
- 137.42
- P/S
- 25.53
- P/B
- 13.33
- EV/EBITDA
- 65.14
- Div Yield
- 0.60%
- Gross Margin
- 94.13%
- Op Margin
- 34.50%
- Net Margin
- 18.59%
- ROE
- 10.44%
- ROIC
- 8.88%
- Revenue
- $1.99B · 674.85%
- Net Income
- $1.02B · 675.88%
- EPS
- $11.52 · 676.00%
- Op Income
- $1.36B
- FCF YoY
- 514.27%
- 52W High
- $38.75
- 52W Low
- $19.34
- 50D MA
- $34.39
- 200D MA
- $33.63
- Beta
- -0.67
- Avg Volume
- 6
Get TickerSpark's AI analysis on BRCTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BRCTF coverage
Recent articles, reports, and earnings notes.
No research on BRCTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BRCTF report →Similar companies
Peers in the same neighborhood.